WuXi Biologics Reports Solid 2025 Interim Results
- Written by PR Newswire
- Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operations was 20.2%
- IFRS Gross profit margin expanded by 3.6% YoY to 42.7%
- EBITDA grew 50.5% YoY and IFRS net profit increased 54.8% YoY
- Adjusted EBITDA grew 20.6% YoY and adjusted net profit increased 11.6% YoY
- FY25 group revenue growth target raised...
